Abstract
Early diagnosis of aortic stenosis (AS) is critical to prevent morbidity and premature mortality but requires skilled examination with Doppler imaging. We hypothesized that self-supervised learning of 2-dimensional parasternal long axis (PLAX) videos from transthoracic echocardiography (TTE) without Doppler imaging could extract discriminative features to identify severe AS suitable for point-of-care ultrasonography. In a training set of 5,311 studies (17,601 videos) from 2016-2020, we performed self-supervised pretraining based on contrastive learning of PLAX videos, then used those learned weights to initialize a convolutional neural network to predict severe AS in an external set of 2,040 studies from 2021. Our model achieved an AUC of 0.97 (95% CI: 0.96-0.99) for detecting severe AS with 95.8% sensitivity and 90% specificity. The models were interpretable with saliency maps identifying the aortic valve as the predictive region. Among non-severe AS cases, predicted probabilities were associated with worse quantitative metrics of AS suggesting association with AS severity. We propose an automated approach for severe AS detection using single-view 2D echocardiography, with implications for point-of-care screening.
Competing Interest Statement
E.K.O. is a co-founder of Evidence2Health, and has served as a consultant for Caristo Diagnostics, Ltd. B.J.M. has a pending patent on predictive models using electronic health records (US20180315507A1). A.H.R. is funded by Kjell och Märta Beijer Foundation. J.K.F. has received grant support/research contracts and consultant fees/honoraria/Speakers Bureau fees from Edwards Lifesciences and Medtronic. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company. R.K. receives research support, through Yale, from Bristol-Myers Squibb. He is also a coinventor of U.S. Pending Patent Applications. 63/177,117, and 63/346,610, unrelated to the current work. He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. The remaining authors have no competing interests to disclose.
Funding Statement
The study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775 to R.K.). A.H.R. is supported in part by CNPq (310679/2016-8 and 465518/2014-1) and by FAPEMIG (PPM-00428-17 and RED-00081-16). R.K. received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award, 2022060). B.J.M. reported receiving grants from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food and Drug Administration, and the US Department of Defense Advanced Research Projects Agency outside the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed by the Yale Institutional Review Board, which approved the study protocol and waived the need for informed consent as the study represents secondary analysis of existing data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are not available for public sharing given the restrictions in our institutional review board approval. The deidentified test set may be available to researchers under a data use agreement after the study has been published in a peer-reviewed journal.
